Table 1.

Demographics of patients receiving CB-derived VST infusions

Patient IDDiagnosisAge, ySexWeight, kgConditioning regimenHLA match (of 6)Immunosuppression before VSTRecipient CMV serostatusTNCs from UCB, × 107TNCs/kg of UCB fraction used for primary transplant
ACT-CAT
 P2891Fanconi anemia5M13.0Flu/Cy/TBI5CSA,MMF, steroidsPositive1619.9
 P3010ALL2M11.0Flu/Cy/TBI5CSA, MMFPositive19113.9
 P3275SCID1M5.2Bu/Cy/Flu6CSA, MMF, steroidsPositive12118.8
 P3317Myelofibrosis2M9.7Bu/Cy/Flu5CSA, MMF, steroidsPositive22518.6
 P3457JMML2M12.3Bu/Cy/Flu5CSA, MMFPositive18512.0
 P3531SCID1M6.4Bu/Cy/Flu5CSA, MMF, steroidsPositive12916.0
 P3555SCID1M8.0Bu/Cy/Flu6CSA, MMF, steroidsPositive11011.0
 P3923AML1F7.0Bu/Cy/Flu5CSA, MMF, steroidsPositive10211.7
 P3626JMML1M9.0Bu/Cy/Flu5CSA, MMFPositive20918.6
ACT-CAT2
 P0020AML3F16.7Bu/Cy5CSA, MMF, steroids, ECPPositive1034.9
 P0035Hurler’s syndrome1.1F8.8Bu/Flu/ATG/ rituximab4CSA, steroidsPositive25222.9
 P0039Infant ALL1.9M12.2Flu/Cy/TBI6CSA, MMF, steroidsPositive674.4
 P0067Sickle cell disease8F19.8Flu/Mel/Thio/alemtuzumab/HU6CSA, MMF, infliximab, steroidsPositive1094.4
 P0123Sickle cell disease4M16.6Flu/Mel/Thio/alemtuzumab/HU5CSA, tacro, MMF, steroidsNegative1979.5
  • ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; Bu, busulfan; CSA, cyclosporin A; Cy, cyclophosphamide; ECP, extracorporeal photopheresis; F, female; Flu, fludarabine; HLA, human leukocyte antigen; HU, hydroxyurea; JMML, juvenile myelomonocytic leukemia; M, male; Mel, melphalan; MMF, mycophenolate mofetil; SCID, severe combined immunodeficiency; tacro, tacrolimus; TBI, total body irradiation; Thio, thiotepa; TNC, total nucleated cells; UCB, umbilical cord blood.